Loading…
Chinese biotech developing biologic drugs for autoimmune diseases and cancer, including telitacicept.
Chinese biotech developing biologic drugs for autoimmune diseases and cancer, including telitacicept.
Earns from sales of its two lead drugs in China, mostly to hospitals, and from licensing: overseas rights to disitamab vedotin were licensed to Seagen, now part of Pfizer, bringing upfront and milestone payments. These are the Hong Kong-listed H shares.
In one line: A Chinese autoimmune/oncology biologics biotech.
Moat: narrow (IP / patents, process know-how). Proprietary biologics platform with first-in-class/best-in-class autoimmune and ADC assets.
Headquarters: Yantai, China · Founded: 2008 · Employees: 3,048
Size RemeGen (9995.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $6.92B, the 214th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$70.20 on 6 Nov 2026.
Performance Over six months the shares fell 30.8%, against +2.6% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 292.8% over the last twelve months (peer median +4.5%); the operating margin is 61.1% (peer median 13.8%).
Valuation It trades at 7.4× forward earnings against a peer median of 27.4× (cheapest of 14).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +58%, so the hurdle is -63 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 108.3 points above its cost of capital (9.3% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$9.46B | HK$3.52B | HK$1.85B | HK$1.19B | HK$893M |
| Revenue growth | — | +90% | +56% | +33% | — |
| Gross profit | HK$8.94B | HK$2.87B | HK$1.35B | HK$715M | HK$362M |
| EBITDA | n/a | HK$481M | -HK$1.45B | -HK$1.48B | -HK$1.19B |
| Net income | HK$7.45B | HK$770M | -HK$1.59B | -HK$1.67B | -HK$1.16B |
| Free cash flow | HK$4.44B | HK$385M | n/a | -HK$2.53B | -HK$2.35B |
| Capital expenditure | HK$153M | HK$216M | n/a | HK$851M | HK$881M |
| Total debt | HK$342M | HK$2.45B | HK$2.84B | HK$1.39B | HK$185M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| RemeGen 9995.HK | $6.92B | -31% | +293% | 61% | 7.4× | -4.8% |
| Innovent Biologics 1801.HK | $19.2B | -5% | +43% | 17% | 53.3× | 11.7% |
| Akeso 9926.HK | $10.2B | -38% | +42% | -25% | n/a | n/a |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | $13.9B | 0% | +44% | -38% | 1,255.9× | 56.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9995.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.4% | +3.2% | 5th lowest of 21 |
| 6-month return | -30.8% | +2.6% | 3rd lowest of 21 |
| Distance from 52-week high | -43.0% | -11.5% | 3rd lowest of 21 |
| Revenue growth (TTM) | +292.8% | +4.5% | highest of 18 |
| Operating margin | 61.1% | 13.8% | highest of 18 |
| Forward P/E | 7.4× | 27.4× | cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | -4.8% | 12.6% | 3rd least demanding of 11 |
| Growth delivered (Del g) | +57.9% | +9.0% | highest of 11 |
| Hurdle (Req g minus delivered) | -62.8 pp | +3.1 pp | least demanding of 11 |
| ROIC minus cost of capital | +108.3 pp | -2.7 pp | highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| RemeGen 9995.HK | Hong Kong | $6.92B | -31% | +293% | 61% | 7.4× | -4.8% | +57.9% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 14.7× | -8.2% | +10.8% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% | +8.7% |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |
| Alkem Laboratories ALKEM.NS | India | $6.67B | -5% | +13% | 17% | 27.4× | 24.3% | +10.7% |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% | +5.3% |
| Ionis Pharmaceuticals IONS | United States | $6.55B | -48% | -7% | -68% | n/a | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 33.1× | n/a | n/a |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% | +45.5% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% | +18.4% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | n/a | n/a | n/a |
| Gan & Lee Pharmaceuticals 603087.SS | China | $6.40B | +21% | +14% | 20% | 29.7× | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.39B | -36% | n/a | -25% | 24.0× | n/a | n/a |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% | +7.1% |
| Biocon BIOCON.NS | India | $6.28B | -4% | +6% | 8% | 56.4× | n/a | n/a |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | n/a | 31.5% | +7.3% |
| Belite Bio, Inc. ADR BLTE | United States | $6.20B | 0% | n/a | n/a | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 32.0× | 20.0% | +9.4% |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | n/a | n/a | n/a |
| Ligand Pharmaceuticals LGND | United States | $6.12B | +38% | +1% | 14% | 28.0× | 57.8% | +7.5% |